Homepage

Becton, Dickinson and Company

BDX NYSE Categories PDF
Healthcare · Medical - Instruments & Supplies
Franklin Lakes, NJ 07417-1880, United States IPO 1973 bd.com Updated Jun 27, 1:54am
Price
$155.92
Market Cap
$56.5B
Employees
70,000
Beta
0.28
Avg Volume
2,845,159
CEO
Thomas E. Polen Jr.
Business Description

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Business History
Price History (1 Year)
Last updated: Jun 27, 2026 1:54am (8h ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Jun 21, 2026 6:42pm (5d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
26.70
Stock Price: $155.92
EPS (Diluted): 5.84
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
1.66
Stock Price: $155.92
Total Equity: $25.39B
Shares: 287,118,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
12.21
Market Cap: $56.49B
Total Debt: $19.18B
Cash: $851.00M
EBITDA: $4.96B
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$60.5B
Market Cap: $56.49B
Total Debt: $19.18B
Cash: $851.00M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
45.4%
Gross Profit: $9.92B
Revenue: $21.84B
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
11.8%
Operating Income: $2.58B
Revenue: $21.84B
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
7.7%
Net Income: $1.68B
Revenue: $21.84B
ROE (Profit from shareholder equity)
CALC
Net Income / Total Equity
6.6%
Net Income: $1.68B
Total Equity: $25.39B
ROIC (Profit from all invested capital)
CALC
NOPAT / Invested Capital
5.3%
Operating Income: $2.58B
Tax Rate: 10.8%
Equity: $25.39B
Total Debt: $19.18B
Cash: $851.00M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.11
Current Assets: $9.26B
Current Liabilities: $8.31B
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.76
Short-Term Debt: $1.56B
Long-Term Debt: $17.62B
Total Debt: $19.18B
Total Equity: $25.39B
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$76.06
Revenue: $21.84B
Shares: 287,118,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$88.43
Total Equity: $25.39B
Shares: 287,118,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$9.30
Operating CF: $3.43B
CapEx: -$760.00M
Shares: 287,118,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
2.8%
Last Dividend: N/A
Stock Price: $155.92
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $1.68B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BDX against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 6:42pm (5d ago)
Metric 2021 2022 2023 2024 2025
Revenue $19.1B $18.9B $19.4B $20.2B $21.8B
Cost of Revenue $10.5B $10.4B $11.2B $11.1B $11.9B
Gross Profit $8.6B $8.5B $8.2B $9.1B $9.9B
Operating Expenses $6.4B $6.2B $6.1B $6.7B $7.3B
Operating Income $2.3B $2.3B $2.1B $2.4B $2.6B
Net Income $2.1B $1.8B $1.5B $1.7B $1.7B
EBITDA $4.4B $4.4B $4.4B $4.8B $5.0B
EPS $6.92 $5.93 $4.97 $5.88 $5.84
EPS (Diluted)
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:42pm (5d ago)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $2.4B $1.2B $1.4B $1.9B $851.0M
Total Current Assets $8.8B $8.1B $8.7B $10.5B $9.3B
Total Assets $53.9B $52.9B $52.8B $57.3B $55.3B
Current Liabilities $6.6B $7.8B $6.6B $9.0B $8.3B
Long-Term Debt $17.5B $14.3B $15.2B $18.6B $17.6B
Total Liabilities $30.2B $27.7B $27.0B $31.4B $29.9B
Total Equity $23.7B $25.3B $25.8B $25.9B $25.4B
Retained Earnings $13.8B $15.2B $15.5B $16.1B $16.6B
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:42pm (5d ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $4.6B $2.6B $3.0B $3.8B $3.4B
Capital Expenditure -$1.2B -$973.0M -$874.0M -$725.0M -$760.0M
Free Cash Flow $3.4B $1.7B $2.1B $3.1B $2.7B
Acquisitions (net) -$508.0M -$2.1B $540.0M -$3.9B $0
Debt Repayment
Dividends Paid
Stock Buybacks -$1.8B -$500.0M $0 -$500.0M -$1.0B
Net Change in Cash -$525.0M -$1.2B $322.0M $375.0M -$1.0B
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 1:54am (8h ago)
Metric 2027 2028 2029 2030
Revenue $19.7B
$19.4B – $20.1B
$20.4B
$20.3B – $20.4B
$21.1B
$21.0B – $21.4B
$21.9B
$21.7B – $22.2B
EBITDA $4.5B
$4.5B – $4.7B
$4.7B
$4.7B – $4.7B
$4.9B
$4.8B – $4.9B
$5.1B
$5.0B – $5.1B
Net Income $4.1B
$3.7B – $4.5B
$4.1B
$4.1B – $4.2B
$4.4B
$4.4B – $4.5B
$4.7B
$4.7B – $4.8B
EPS
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:42pm (5d ago)
Metric 2022 2023 2024 2025
Revenue Growth -1.4% +2.7% +4.2% +8.2%
Gross Profit Growth -1.8% -3.6% +11.7% +8.8%
Operating Income Growth +1.4% -7.5% +13.5% +7.6%
Net Income Growth -15.0% -16.6% +14.9% -1.6%
EBITDA Growth +0.4% -0.2% +9.5% +2.9%
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:42pm (5d ago)
Date Dividend Declaration Record Payment
2026-06-09 $1.05 2026-04-28 2026-06-09 2026-06-30
2026-03-10 $1.05 2026-01-27 2026-03-10 2026-03-31
2025-12-08 $1.05 2025-11-06 2025-12-08 2025-12-31
2025-09-08 $1.04 2025-07-22 2025-09-08 2025-09-30
2025-06-09 $1.04 2025-04-29 2025-06-09 2025-06-30
2025-03-10 $1.04 2025-01-28 2025-03-10 2025-03-31
2024-12-09 $1.04 2024-11-07 2024-12-09 2024-12-31
2024-09-09 $0.95 2024-07-23 2024-09-09 2024-09-30
2024-06-10 $0.95 2024-04-30 2024-06-10 2024-06-28
2024-03-07 $0.95 2024-01-23 2024-03-08 2024-03-29
2023-12-07 $0.95 2023-11-09 2023-12-08 2023-12-29
2023-09-07 $0.91 2023-07-25 2023-09-08 2023-09-29
2023-06-08 $0.91 2023-04-25 2023-06-09 2023-06-30
2023-03-09 $0.91 2023-01-24 2023-03-10 2023-03-31
2022-12-08 $0.91 2022-11-10 2022-12-09 2022-12-30
2022-09-08 $0.87 2022-07-26 2022-09-09 2022-09-30
2022-06-08 $0.87 2022-04-26 2022-06-09 2022-06-30
2022-03-09 $0.87 2022-01-25 2022-03-10 2022-03-31
2021-12-09 $0.87 2021-11-04 2021-12-10 2021-12-31
2021-09-08 $0.83 2021-07-27 2021-09-09 2021-09-30
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BDX — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for BDX. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30